Role of interleukin‐7 in fusion of rat bone marrow mesenchymal stem cells with cardiomyocytes in vitro and improvement of cardiac function in vivo. Issue 6 (6th December 2018)
- Record Type:
- Journal Article
- Title:
- Role of interleukin‐7 in fusion of rat bone marrow mesenchymal stem cells with cardiomyocytes in vitro and improvement of cardiac function in vivo. Issue 6 (6th December 2018)
- Main Title:
- Role of interleukin‐7 in fusion of rat bone marrow mesenchymal stem cells with cardiomyocytes in vitro and improvement of cardiac function in vivo
- Authors:
- Haneef, Kanwal
Ali, Anwar
Khan, Irfan
Naeem, Nadia
Jamall, Siddiqua
Salim, Asmat - Abstract:
- Summary: Aims: Mesenchymal stem cells (MSCs) hold significant promise as potential therapeutic candidates following cardiac injury. However, to ensure survival of transplanted cells in ischemic environment, it is beneficial to precondition them with growth factors that play important role in cell survival and proliferation. Aim of this study is to use interleukin‐7 (IL‐7), a cell survival growth factor, to enhance the potential of rat bone marrow MSCs in terms of cell fusion in vitro and cardiac function in vivo. Methods: Mesenchymal stem cells were transfected with IL‐7 gene through retroviral vector. Normal and transfected MSCs were co‐cultured with neonatal cardiomyocytes (CMs) and cell fusion was analyzed by flow cytometry and fluorescence microscopy. These MSCs were also transplanted in rat model of myocardial infarction (MI) and changes at tissue level and cardiac function were assessed by histological analysis and echocardiography, respectively. Results: Co‐culture of IL‐7 transfected MSCs and CMs showed significantly higher ( P < 0.01) number of fused cells as compared to normal MSCs. Histological analysis of hearts transplanted with IL‐7 transfected MSCs showed significant reduction ( P < 0.001) in infarct size and better preservation ( P < 0.001) of left ventricular wall thickness as compared to normal MSCs. Presence of cardiac‐specific proteins, α‐actinin, and troponin‐T showed that the transplanted MSCs were differentiated into cardiomyocytes.Summary: Aims: Mesenchymal stem cells (MSCs) hold significant promise as potential therapeutic candidates following cardiac injury. However, to ensure survival of transplanted cells in ischemic environment, it is beneficial to precondition them with growth factors that play important role in cell survival and proliferation. Aim of this study is to use interleukin‐7 (IL‐7), a cell survival growth factor, to enhance the potential of rat bone marrow MSCs in terms of cell fusion in vitro and cardiac function in vivo. Methods: Mesenchymal stem cells were transfected with IL‐7 gene through retroviral vector. Normal and transfected MSCs were co‐cultured with neonatal cardiomyocytes (CMs) and cell fusion was analyzed by flow cytometry and fluorescence microscopy. These MSCs were also transplanted in rat model of myocardial infarction (MI) and changes at tissue level and cardiac function were assessed by histological analysis and echocardiography, respectively. Results: Co‐culture of IL‐7 transfected MSCs and CMs showed significantly higher ( P < 0.01) number of fused cells as compared to normal MSCs. Histological analysis of hearts transplanted with IL‐7 transfected MSCs showed significant reduction ( P < 0.001) in infarct size and better preservation ( P < 0.001) of left ventricular wall thickness as compared to normal MSCs. Presence of cardiac‐specific proteins, α‐actinin, and troponin‐T showed that the transplanted MSCs were differentiated into cardiomyocytes. Echocardiographic recordings of the experimental group transplanted with transfected MSCs showed significant increase in the ejection fraction and fractional shortening ( P < 0.01), and decrease in diastolic and systolic left ventricular internal diameters ( P < 0.001) and end systolic and diastolic volumes ( P < 0.01 and P < 0.001, respectively). Conclusion: Interleukin‐7 is able to enhance the fusogenic properties of MSCs and improve cardiac function. This improvement may be attributed to the supportive action of IL‐7 on cell proliferation and cell survival contributing to the regeneration of damaged myocardium. … (more)
- Is Part Of:
- Cardiovascular therapeutics. Volume 36:Issue 6(2018)
- Journal:
- Cardiovascular therapeutics
- Issue:
- Volume 36:Issue 6(2018)
- Issue Display:
- Volume 36, Issue 6 (2018)
- Year:
- 2018
- Volume:
- 36
- Issue:
- 6
- Issue Sort Value:
- 2018-0036-0006-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2018-12-06
- Subjects:
- cell therapy -- cytokine -- differentiation -- myocardial infarction -- survival -- transplantation
Cardiovascular pharmacology -- Periodicals
Cardiovascular agents -- Periodicals
Cardiovascular system -- Diseases -- Chemotherapy -- Periodicals
Cardiovascular Agents -- Periodicals
Cardiovascular Diseases -- drug therapy -- Periodicals
Agents cardiovasculaires -- Périodiques
Appareil cardiovasculaire -- Maladies -- Chimiothérapie -- Périodiques
616.1005 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1755-5922 ↗
http://www.blackwell-synergy.com/loi/cath ↗
http://www.blackwellpublishing.com/journal.asp?ref=1755-5914&site=1 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/1755-5922.12479 ↗
- Languages:
- English
- ISSNs:
- 1755-5914
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3051.520500
British Library HMNTS - ELD Digital store - Ingest File:
- 11708.xml